Movatterモバイル変換

[0]ホーム
URL:

Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
Thehttps:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

NIH NLM Logo
Log inShow account info
Access keysNCBI HomepageMyNCBI HomepageMain ContentMain Navigation
pubmed logo
Advanced Clipboard
User Guide

Full text links

book cover photo
StatPearls [Internet]
NCBI Bookshelf
Full text links

Actions

Share

Book

Antifungal Ergosterol Synthesis Inhibitors

In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan.
.
Affiliations
Free Books & Documents
Book

Antifungal Ergosterol Synthesis Inhibitors

Elizabeth J. Herrick et al.
Free Books & Documents

Excerpt

This activity delves into the pharmacological intricacies of antifungal ergosterol synthesis inhibitors, commonly called "azoles." These medications, encompassing miconazole, ketoconazole, fluconazole, itraconazole, voriconazole, posaconazole, isavuconazole, and oteseconazole, play a crucial role in managing diverse fungal infections. The primary mechanism of action involves the inhibition of ergosterol biosynthesis, leading to the disruption of fungal cell membrane integrity. Exploring these azole antifungal agents involves covering indications, contraindications, drug interactions, and adverse event profiles. Notably, the potential for hepatotoxicity necessitates vigilant monitoring and interprofessional communication. These agents' scientific and medical examination includes in-depth discussions on pharmacokinetics, monitoring protocols, clinical toxicology, and elucidating significant box warnings.

Copyright © 2025, StatPearls Publishing LLC.

PubMed Disclaimer

Conflict of interest statement

Disclosure:Elizabeth Herrick declares no relevant financial relationships with ineligible companies.

Disclosure:Preeti Patel declares no relevant financial relationships with ineligible companies.

Disclosure:Muhammad Hashmi declares no relevant financial relationships with ineligible companies.

Sections

Similar articles

See all similar articles

References

    1. Gallagher JC, Dodds Ashley ES, Drew RH, Perfect JR. Antifungal pharmacotherapy for invasive mould infections. Expert Opin Pharmacother. 2003 Feb;4(2):147-64. - PubMed
    1. Peyton LR, Gallagher S, Hashemzadeh M. Triazole antifungals: a review. Drugs Today (Barc) 2015 Dec;51(12):705-18. - PubMed
    1. Heeres J, Meerpoel L, Lewi P. Conazoles. Molecules. 2010 Jun 09;15(6):4129-88. - PMC - PubMed
    1. Poojary S, Miskeen A, Bagadia J, Jaiswal S, Uppuluri P. A Study of In vitro Antifungal Susceptibility Patterns of Dermatophytic Fungi at a Tertiary Care Center in Western India. Indian J Dermatol. 2019 Jul-Aug;64(4):277-284. - PMC - PubMed
    1. Rauseo AM, Mazi P, Lewis P, Burnett B, Mudge S, Spec A. Bioavailability of Single-Dose SUBA-Itraconazole Compared to Conventional Itraconazole under Fasted and Fed Conditions. Antimicrob Agents Chemother. 2021 Jul 16;65(8):e0013421. - PMC - PubMed

Publication types

LinkOut - more resources

Full text links
book cover photo
StatPearls [Internet]
NCBI Bookshelf
Cite
Send To

NCBI Literature Resources

MeSHPMCBookshelfDisclaimer

The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.

[8]ページ先頭
©2009-2025 Movatter.jp